Core Viewpoint - The company, BWS (碧水源), clarified on an interactive platform that the collection of accounts receivable should be based on the sales amount reported in the cash flow statement of its periodic reports [1] Group 1 - The company responded to investor inquiries regarding accounts receivable collection [1] - The company emphasized the importance of referring to the cash flow statement for accurate sales figures [1]

Core Viewpoint - The company emphasizes that its stock price fluctuations are influenced by various factors, including market conditions and investor preferences, and it is committed to enhancing its market performance through strategic initiatives [1] Group 1: Company Strategy and Management - The company management places high importance on market value management, integrating it into the performance assessment system [1] - The company will continue to focus on its core business, improving operational efficiency and profitability [1] - The company is advancing its "12256" strategy to enhance overall value and market performance [1] Group 2: Governance and Disclosure - The company adheres strictly to the disclosure requirements of the stock exchange, confirming that there are no undisclosed matters related to shareholding changes [1] - The controlling shareholder's ownership ratio remains stable, and the board of directors holds a majority of seats, ensuring stable governance at both the shareholder meeting and board levels [1]

Core Viewpoint - The company, BWS (碧水源), addressed investor inquiries regarding its accounts receivable situation, advising stakeholders to refer to its periodic reports for detailed information [1] Summary by Category Company Information - BWS responded to investor questions on its interactive platform about accounts receivable [1] - The company emphasized that detailed information can be found in its regular financial reports [1]

Group 1 - The core viewpoint of the article is that the company, BWS (碧水源), has developed reverse osmosis membranes and adsorbents that effectively remove fluoride from water, indicating a potential application in wastewater treatment projects in chemical industrial bases [1] Group 2 - The company's products are currently being utilized in certain wastewater treatment projects, showcasing their practical application in the industry [1]

Core Viewpoint - As of November 20, the number of shareholders for BWS (碧水源) reached 75,238 households [1] Company Summary - BWS has actively engaged with investors through an interactive platform, providing updates on shareholder statistics [1]

关于北京碧水源科技股份有限公司 2025 年第二次临时股东会的法律意见书 齐致股见证字[2025]第 042 号 致：北京碧水源科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）和《上市公司 股东会规则》等法律、法规和规范性文件以及《北京碧水源科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，北京市齐致律师事务所（以下简称 "本所"）受北京碧水源科技股份有限公司（以下简称"碧水源公司"）委托， 指派本所王海军律师、王玉林律师列席了碧水源公司 2025 年第二次临时股东会 （以下简称"本次临时股东会"），并就本次临时股东会进行见证，出具本见证 意见。 为出具本见证意见，本所律师审查了碧水源公司本次临时股东会的有关文件 和材料。本所律师得到碧水源公司如下保证，即其已提供了本所律师认为作为出 具本见证意见所必需的材料，所提供的原始材料、副本、复印件等材料、口头证 言均符合真实、准确、完整的要求，有关副本、复印件等材料与原始材料一致。 在本见证意见中，本所律师依法仅对本次股东会所涉及的召集、召开程序、 出席会议的人员资格及会议表决程序、表决结果是否符合《公司法》《上市公司 股东会规则》 ...

出席本次会议的股东及股东代表共 653 人，代表公司有表决权的股份 1,486,551,694 股，占公司有表决权股份总数的 41.02%。其中：出席现场会议的 股东及股东代表 2 人，所持有表决权股份 1,309,443,052 股，占公司有表决权股 份总数的 36.13%；参加网络投票的股东 651 人，所持有表决权股份 177,108,642 股，占公司有表决权股份总数的 4.89%。 本次会议召集人为公司董事会，会议由董事长黄江龙先生主持，公司董事、 部分高级管理人员、公司聘请的见证律师等相关人员出席了本次股东会。会议的 召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》的规定。 证券代码：300070 证券简称：碧水源 公告编号：2025-070 北京碧水源科技股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 一、会议召开和出席情况 2025年11月15日，北京碧水源科技股份有限公司（以下简称"公司")董事 会以公告的方式向全体股东发出召开2025年第二次临时股东会的通知，本次会 ...

Core Viewpoint - The company, Beijing Biyuan Technology Co., Ltd., is focusing on high-quality development and strategic transformation in the environmental technology sector, emphasizing its comprehensive business layout in water treatment and related fields [1][2]. Group 1: Business Overview and Strategic Transformation - The company has a full industry chain layout in water treatment, with core technologies including microfiltration, ultrafiltration, nanofiltration, and reverse osmosis [1]. - The strategic shift is from "large investment, large projects, large growth" to "high innovation, high intelligence, high environmental value," guided by the "12256" strategy to enhance the proportion of high value-added businesses [2]. Group 2: Industrial Wastewater Treatment Progress - The company has made significant breakthroughs in industrial wastewater treatment, recently winning two major projects in Northeast China with a total value exceeding 3 billion yuan [3]. - Specific projects include a 1.52 billion yuan industrial wastewater treatment project in Liaoning and a 1.98 billion yuan total contracting project in Liao Yuan, focusing on pharmaceutical and chemical enterprises [3]. Group 3: Lithium Extraction from Salt Lakes - The company has transitioned from research to project expansion in lithium extraction from salt lakes, developing specialized adsorbents and establishing partnerships with companies like Zijin Mining [4]. Group 4: Pharmaceutical Membrane Business - The pharmaceutical membrane business aims to create new advantages in life and health separation and purification, focusing on protein separation and virus removal [5]. - Recent breakthroughs include developments in four product categories, with support from the Beijing Science and Technology Commission for virus removal membrane products [5]. Group 5: Accounts Receivable Management - The company is addressing accounts receivable pressures through tailored strategies for loss-making entities, establishing special teams for debt recovery, and participating in local government debt resolution efforts [6]. - The company reports gradual improvements in debt recovery outcomes and aims to enhance core competitiveness through technological innovation and industrial integration [6].

Group 1: Company Overview and Core Business - Beijing BWS Technology Co., Ltd. specializes in environmental protection and water treatment, with a comprehensive layout in the water treatment industry [2] - The company has developed core advantages in membrane material research, equipment manufacturing, and digital water management, holding proprietary technologies in microfiltration, ultrafiltration, nanofiltration, and reverse osmosis [2] - BWS operates advanced membrane production bases in Beijing and Tianjin, with a capacity of 20 million square meters for microfiltration/ultrafiltration membranes and 19 million square meters for nanofiltration/reverse osmosis membranes annually [2] Group 2: Strategic Development and Business Focus - The company is implementing the "12256" strategy to enhance operational quality and efficiency, focusing on high-value-added business segments [3] - BWS aims to transition from "large investment, large projects, large growth" to "high innovation, high intelligence, high environmental quality" [3] - The company is expanding into high-value sectors such as industrial water treatment, seawater resource utilization, and lithium extraction from salt lakes [3] Group 3: Recent Project Developments - In the industrial wastewater treatment sector, BWS has secured projects in Northeast China, including a 1.52 billion yuan project in Liaoning with a 40-year concession period [3] - The company also won a 1.98 billion yuan total contracting project in Liaoyuan, focusing on pharmaceutical and chemical enterprises [3] - A project in Shandong for upgrading and expanding capacity was valued at 66.9 million yuan, aimed at better water resource utilization [3] Group 4: Innovations in Health Sector - BWS is developing a pharmaceutical membrane business, focusing on protein separation and virus removal, aligning with national bio-economy strategies [4] - The company has formed a dedicated team for biopharmaceutical membrane development, achieving breakthroughs in four product categories, including ATF perfusion series and virus removal membranes [4] Group 5: Financial Management and Accounts Receivable - BWS is addressing pressures from accounts receivable, a legacy of previous expansive growth, and is implementing measures to improve collection [5] - The company has established a special team for debt recovery and is actively participating in local government debt resolution efforts [5] - Recent measures have shown gradual improvement in accounts receivable recovery [5]

进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为527.23万元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | | | | 48.00 | 203.52 | 4.24 | 0.47 | 光大证券股份有限公司宁 | 光大证券股份有限公司宁 | | | | | | 波柳汀街证券营业部 | 波柳汀街证券营业部 | 证券时报·数据宝统计显示，碧水源今日收盘价为4.22元，下跌0.24%，日换手率为0.47%，成交额为 6682.67万元，全天主力资金净流出206.74万元，近5日该股累计下跌5.17%，近5日资金合计净流出 4776.30万元。 （文章来源：证券时报网） 两融数据显示，该股最新融资余额为7.80亿元，近5日减少828.08万元，降幅为1.05%。 据天眼查APP显示，北京碧水源科技股份有限公司成立于2001年07月17日，注册资本362420.9363万人 民币。（数据宝） 碧水源11月27日大宗交易平 ...